GlassScriptPhysician profile
Robert Leslie Moss
NPI 1659304871
$6,760.28
in general payments reported to CMS, 2019-2025
47 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,912 · 2020: $325 · 2021: $145 · 2022: $754 · 2023: $836 · 2024: $1,541 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.15 | 2019-2025 | |
| Novo Nordisk INC | $736.96 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $547.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $544.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $408.22 | 2021-2025 | |
| Amgen INC. | $349.70 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $287.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.96 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $195.37 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $154.11 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $131.81 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $124.58 | 2019-2024 | Eliquis, Camzyos |
| Sunovion Pharmaceuticals INC. | $95.42 | 2019-2020 | |
| Dexcom, INC. | $88.74 | 2023-2025 | Dexcom G6 Transmitter |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.